CORRECTION article

Front. Pharmacol., 12 May 2023

Sec. Inflammation Pharmacology

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1199951

Corrigendum: Deferoxamine alleviates osteoarthritis by inhibiting chondrocyte ferroptosis and activating the Nrf2 pathway

  • 1. Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • 2. Michigan State University’s Broad College of Business, East Lansing, MI, United States

  • 3. Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

  • 4. Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Article metrics

View details

8

Citations

2k

Views

1,1k

Downloads

In the published article, there was an error in (Figure 3H) as published. (Due to the error of data filing, the fluorescence images of the Erastin group in Figure 3H was inserted incorrectly). The corrected (Figure 3H) and its caption (Erastin initiated inflammation responses and ECM degradation in chondrocytes that could be alleviated by Ferrostatin-1) appear below.

FIGURE 3

In the published article, there was an error in (Figure 5F) as published. (Due to the error of data filing, the fluorescence images of the Control group in Figure 5F was inserted incorrectly). The corrected (Figure 5F) and its caption (DFO alleviated chondrocytes ferroptosis and OA progress induced by erastin) appear below.

FIGURE 5

In the published article, there was an error. (There is a clerical error in the Materials and Methods section).

A correction has been made to (Materials and Methods), (Animal experiment). This sentence previously stated:

“(the sham group, DMM group, DMM + DFO (10 mg/kg) group, DMM + DFO (100 mg/kg) group, erastin group, erastin (15 mg/kg) + DFO (10 mg/kg) group, and erastin (15 mg/kg) + DFO (100 mg/kg) group.)”

The corrected sentence appears below:

“(the sham group, DMM group, DMM + DFO (10 mg/kg) group, DMM + DFO (100 mg/kg) group, erastin group, erastin (5 mg/kg) + DFO (10 mg/kg) group, and erastin (5 mg/kg) + DFO (100 mg/kg) group.)”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

osteoarthritis, chondrocytes, ferroptosis, deferoxamine, Nrf2

Citation

Guo Z, Lin J, Sun K, Guo J, Yao X, Wang G, Hou L, Xu J, Guo J and Guo F (2023) Corrigendum: Deferoxamine alleviates osteoarthritis by inhibiting chondrocyte ferroptosis and activating the Nrf2 pathway. Front. Pharmacol. 14:1199951. doi: 10.3389/fphar.2023.1199951

Received

04 April 2023

Accepted

20 April 2023

Published

12 May 2023

Volume

14 - 2023

Edited and reviewed by

Dieter Steinhilber, Goethe University Frankfurt, Germany

Updates

Copyright

*Correspondence: Fengjing Guo,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics